Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 test-negative study of 20-valent pneumococcal conjugate vaccine effectiveness against vaccine-type community-acquired pneumonia in adults aged 65 years and older
MOH_2024-01-18_013195Phase 4Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 20 in pneumococcal community-acquired pneumonia (2 arms), sponsored by Pfizer. Primary endpoint: Vaccine effectiveness against vaccine-type radiologically confirmed community-acquired pneumonia. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal community-acquired pneumonia
Beyond the preview
Go deeper on MOH_2024-01-18_013195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-18_013195.